Skip to main content

Table 2 Treatment Patterns of the First Daratumumab-Based Regimen

From: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study

 

All patients

Frontline daratumumab patients

Daratumumab initiated in 2 L

Daratumumab initiated in 3 L+

N = 299

N = 26

N = 66

N = 207

Duration of follow-up1 (months), mean ± SD [median]

18.4 ± 12.5 [16.6]

9.7 ± 6.7 [7.5]

19.2 ± 11.6 [16.9]

19.3 ± 12.9 [17.2]

Number of lines of therapy received prior to daratumumab initiation, mean ± SD [median]

2.4 ± 1.6 [2.0]

0.0 ± 0.0 [0.0]

1.0 ± 0.0 [1.0]

3.2 ± 1.4 [3.0]

Number of regimens2 received prior to daratumumab initiation, mean ± SD [median]

3.2 ± 2.0 [3.0]

0.0 ± 0.0 [0.0]

1.8 ± 1.0 [1.0]

4.1 ± 1.7 [4.0]

First daratumumab regimen2, n (%)

 DPd

113 (37.8)

0 (0.0)

16 (24.2)

97 (46.9)

 Daratumumab (monotherapy)

51 (17.1)

0 (0.0)

6 (9.1)

45 (21.7)

 DRd

49 (16.4)

9 (34.6)

18 (27.3)

22 (10.6)

 DVd

31 (10.4)

3 (11.5)

17 (25.8)

11 (5.3)

 DVMP

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Other regimens

55 (18.4)

14 (53.8)

9 (13.6)

32 (15.5)

  Bortezomib + daratumumab + lenalidomide ± dexamethasone

18 (6.0)

12 (46.2)

6 (9.1)

0 (0.0)

  Carfilzomib + daratumumab ± dexamethasone

7 (2.3)

0 (0.0)

0 (0.0)

7 (3.4)

  Carfilzomib + daratumumab + pomalidomide ± dexamethasone

3 (1.0)

0 (0.0)

1 (1.5)

2 (1.0)

  Daratumumab + ixazomib + pomalidomide ± dexamethasone

2 (0.7)

0 (0.0)

0 (0.0)

2 (1.0)

  Other

25 (8.4)

2 (7.7)

2 (3.0)

21 (10.1)

Received a stem cell transplant prior to initiating daratumumab, n (%)

110 (36.8)

0 (0.0)

19 (28.8)

91 (44.0)

Regimen type of daratumumab-based therapy3, n (%)

 Induction therapy

140 (46.8)

25 (96.2)

32 (48.5)

83 (40.1)

 Conditioning therapy

65 (21.7)

1 (3.8)

12 (18.2)

52 (25.1)

 Consolidation therapy

23 (7.7)

0 (0.0)

6 (9.1)

17 (8.2)

 Maintenance therapy post-stem cell transplant

9 (3.0)

0 (0.0)

1 (1.5)

8 (3.9)

 Bridging therapy

2 (0.7)

0 (0.0)

1 (1.5)

1 (0.5)

 Unknown/non applicable

80 (26.8)

1 (3.8)

17 (25.8)

62 (30.0)

Length of regimen (months), mean ± SD [median]

10.3 ± 10.7 [6.5]

6.9 ± 5.8 [4.1]

12.3 ± 10.5 [8.8]

10.1 ± 11.1 [6.4]

  1. Abbreviations: 2 L: second-line; 3 L: third-line; DPd: daratumumab, pomalidomide, and dexamethasone; DRd: daratumumab, lenalidomide, and dexamethasone; DVd: daratumumab, bortezomib, and dexamethasone; DVMP: daratumumab, bortezomib, melphalan, and prednisone; SD: standard deviation
  2. Notes
  3. [1] Follow-up was defined as the number of months between the index date and the latest of 1) the end date of the last regimen entered (or date of chart abstraction if the last regimen entered was ongoing at the time of entry), 2) the last recorded best response to a regimen, or 3) death
  4. [2] Regimens consisting of the same agents with or without dexamethasone were reported as the same regimen
  5. [3] Each daratumumab-based regimen may have > 1 regimen type
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us